Medicare Advantage 2027 Final Rule: What Plans Must Do Now

On April 6, 2026, CMS published the final rule titled Medicare Program; Contract Year 2027 and Certain Contract Year 2026 Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, and Medicare Cost Plan Programs (Federal Register document 2026-06600). This is not a minor housekeeping rule. It touches Star Ratings methodology, marketing and communications standards, Part D drug coverage requirements, enrollment processes, and Special Needs Plan (SNP) rules — simultaneously and with different effective dates depending on which provision you're looking at.

If your organization sponsors, administers, or supports a Medicare Advantage (MA) or Part D plan, you need to understand which changes are already in effect for contract year 2026, which kick in for contract year 2027, and what your compliance calendar should look like right now.

What Changed and Why It Matters

CMS has been ratcheting up its expectations for MA and Part D plan quality, transparency, and beneficiary protection for several years. This final rule accelerates that trajectory. According to CMS, approximately 33 million beneficiaries are enrolled in Medicare Advantage plans as of 2026, representing about 54% of the total Medicare population — a figure that has nearly doubled over the past decade. The scale of that enrollment means that compliance failures don't just carry regulatory risk; they affect real people in large numbers.

The rule also arrives in a period of heightened enforcement. CMS issued more than $40 million in civil monetary penalties against MA and Part D plan sponsors between 2021 and 2025. The agency has made clear that it views this rule as a vehicle for tightening the accountability framework, not just adjusting technical parameters.

Here is a breakdown of the major regulatory areas affected.

Star Ratings: New Methodology and Guardrails

What changed: The final rule modifies how CMS calculates and applies Star Ratings for contract year 2027 plans. Key adjustments include changes to the guardrail policy that limits how far a measure's cut points can shift from year to year, revisions to the consolidation methodology when plans merge or are acquired, and updates to how certain patient experience and complaints measures are weighted.

Why it matters: Star Ratings are not an academic exercise — they directly determine bonus payments under the Quality Bonus Payment (QBP) program. Plans rated 4 stars or higher qualify for enhanced benchmark payments that can fund supplemental benefits. Falling below 3 stars triggers a range of adverse consequences including potential termination of the contract. In contract year 2025, CMS data showed that plans rated 4 stars or above received per-member-per-month bonuses averaging approximately $170 more than plans below that threshold.

What to do now:

• Review your current measure-level performance against the revised cut points CMS has published for CY2027.
• Pay particular attention to the guardrail changes — if you were relying on stable cut points to forecast your ratings trajectory, recalibrate now.
• If your plan was involved in a merger or acquisition in the past 18 months, work with your compliance team to understand exactly how CMS's consolidation methodology will treat your combined contract's performance data.
• Update your QAPI (Quality Assessment and Performance Improvement) work plan to reflect the revised weighting of patient experience measures.

Marketing and Communications: Tighter Standards, Real Deadlines

What changed: The rule strengthens restrictions on MA plan marketing practices, extending and codifying certain guardrails that had previously been proposed or implemented on a temporary basis. This includes requirements around the use of government-like imagery in marketing materials, limitations on the use of benefit comparison tools by third-party marketing organizations (TPMOs), and stricter disclaimer requirements.

Specifically, CMS is reinforcing the requirement under 42 CFR § 422.2268 that MA organizations ensure all marketing materials — including those produced by downstream TPMOs — comply with CMS's marketing guidelines prior to distribution. The rule clarifies that plan sponsors bear accountability for TPMO marketing violations even when the materials were not produced in-house.

Why it matters: Marketing and communications violations have been among the most commonly cited findings in CMS audit results over the past three contract years. The agency's Audit and Enforcement Reports have repeatedly flagged misleading benefit advertising, incomplete TPMO oversight, and non-compliant enrollment scripts as high-priority issues.

What to do now:

• Audit your current TPMO oversight process end-to-end. If you don't have a documented TPMO monitoring program with evidence of pre-distribution material review, build one.
• Review all current marketing materials against the updated imagery and disclaimer standards before the next annual enrollment period (AEP), which opens October 15.
• Update your downstream entity contracts to include the specific compliance obligations imposed by this rule, and retain documentation that your TPMOs have acknowledged those obligations.
• Train your sales and marketing staff on the revised standards — and document the training.

Part D Drug Coverage: Formulary and Coverage Determination Changes

What changed: The rule makes several adjustments to Part D coverage requirements, including changes to how plans must handle coverage determinations for drugs in protected classes, requirements around formulary transparency, and updates to the transition fill policy for new enrollees.

Under the revised transition fill requirements, plans must ensure that new Part D enrollees receive a temporary supply of non-formulary drugs for a defined transition period to prevent gaps in therapy. The rule tightens the notice requirements that accompany transition fills so that beneficiaries receive clearer, more actionable information about their coverage options.

The rule also addresses cost-sharing standards for certain drug categories, consistent with the continued implementation of the Inflation Reduction Act's prescription drug provisions.

What to do now:

• Review your formulary against the updated protected class requirements and confirm that coverage determination processes for those drugs meet the revised standards.
• Update your transition fill notices to reflect the new content requirements. This is a material change to a beneficiary-facing document and should be treated as a formal document control action.
• Confirm that your pharmacy network and PBM agreements reflect the transition fill obligations and that your system can actually execute those fills within the required timeframes — a policy-document update alone is not enough.

Enrollment Processes: New Accuracy Standards

What changed: CMS is implementing changes to enrollment-related processes intended to reduce errors in enrollment transactions and improve data accuracy between plans and CMS systems. This includes updates to how Special Enrollment Period (SEP) eligibility is verified and how plans handle enrollment transactions that are returned with discrepancies.

What to do now:

• Review your enrollment operations team's procedures for handling returned or rejected transactions and compare them against the updated requirements.
• If your organization relies on a third-party enrollment administrator, confirm they are aware of the rule changes and have updated their processes accordingly. Your contract with that vendor should already include a compliance update obligation — if it doesn't, add one.
• Document the effective date of your process updates. CMS auditors look for evidence of timely implementation, not just eventual compliance.

Special Needs Plans: Updated Requirements

What changed: The rule includes updates to requirements for Dual Eligible Special Needs Plans (D-SNPs) and Chronic Condition Special Needs Plans (C-SNPs), including changes to how these plans document and demonstrate alignment with their target population's needs. CMS is also clarifying expectations around the Individualized Care Plan (ICP) requirements for D-SNP enrollees.

D-SNPs serve some of the most medically and socially complex beneficiaries in the Medicare system. CMS has made clear through both rulemaking and audit activity that it views weak ICP processes as a serious compliance gap — not a minor documentation deficiency.

What to do now:

• Review your ICP development and update workflows against the clarified requirements and confirm that your timeframes, documentation content, and staff accountabilities are all clearly defined.
• If your D-SNP has a Memorandum of Understanding (MOU) with your state Medicaid agency, review whether any provisions of that MOU need to be updated in light of the new rule.
• Assess whether your clinical staff have been trained on the updated ICP expectations and document that training.

Effective Dates: What Applies When

This is where plans often get tripped up. The rule title itself acknowledges that some provisions apply to contract year 2026 and others to contract year 2027. Here is a working summary:

Note: Plans should confirm specific effective dates for each provision by reviewing the preamble and regulatory text at 42 CFR Parts 417, 422, and 423, as published in Federal Register document 2026-06600.

The provisions flagged as CY2026 are not aspirational. They are in effect now, and CMS can cite plan sponsors for non-compliance during any audit or monitoring activity conducted after the publication date.

What I Think Plans Are Getting Wrong Right Now

In my experience working with MA and Part D organizations across the country, the pattern I see most often is that plans read a final rule summary, update one or two internal policies, and call it done. That is not compliance — that is documentation theater. The real work is tracing each regulatory change through to its operational impact: the staff member who does the thing differently, the system that processes the transaction differently, the vendor who produces the material differently.

This rule is particularly tricky because of the split effective dates. I've already heard from plan compliance officers who were treating all of the CY2027 provisions as "next year's problem." The marketing and TPMO oversight changes are not next year's problem. They're this quarter's problem, and the AEP window will be here before most plans have finished their gap assessments.

The practical starting point is a provision-by-provision impact assessment mapped to your operational workflows. Not a high-level summary — a granular walkthrough of what each change requires at the process level, who owns it, and when it needs to be done. If you haven't started that, start now.

A Compliance Checklist for Plan Sponsors

Use this as a starting framework — it is not exhaustive, but it covers the highest-priority actions across the major regulatory areas:

Immediate (before next AEP): - [ ] Conduct TPMO marketing material audit against updated standards - [ ] Update TPMO oversight contracts and acknowledgment documentation - [ ] Review D-SNP ICP workflows against clarified requirements - [ ] Train relevant staff on marketing and ICP changes and document training

Before January 1, 2027: - [ ] Recalibrate Star Ratings forecast model using revised cut points and guardrails - [ ] Update Part D transition fill notices with required content changes - [ ] Revise enrollment transaction error-handling procedures - [ ] Confirm PBM and pharmacy network alignment with updated Part D requirements

Ongoing: - [ ] Monitor CMS audit and enforcement communications for implementation guidance - [ ] Maintain documentation trail for all process updates with effective dates - [ ] Review MOU provisions for D-SNPs that may require state coordination

How Certify Consulting Can Help

At Certify Consulting, we work with health plan sponsors, managed care organizations, and their downstream partners to navigate exactly this kind of complex, multi-provision rulemaking. With more than 200 clients served and a 100% first-time audit pass rate, I know what CMS auditors look for and where plan sponsors tend to leave gaps.

Whether you need a gap assessment against this final rule, help building your TPMO oversight program, or support developing your QAPI work plan around the revised Star Ratings methodology, we can get you there. Learn more about our Medicare Advantage compliance consulting services and how we approach regulatory readiness for Part C and Part D plan sponsors.

You can also explore our resources on healthcare regulatory compliance for broader context on how this rule fits into CMS's longer-term enforcement trajectory.

Source: Federal Register document 2026-06600, published April 6, 2026. Available at https://www.federalregister.gov/documents/2026/04/06/2026-06600/medicare-program-contract-year-2027-and-certain-contract-year-2026-policy-and-technical-changes-to

Last updated: 2026-04-22